Kidney transplant drug dosing gets a closer look
NCT ID NCT01435291
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at how the drug Advagraf (a form of tacrolimus) works in 45 adults who received a kidney transplant. The goal was to find better ways to dose the drug by measuring its levels in the blood right after transplant and three months later. Researchers compared Advagraf with another version of the same drug called Prograf.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Advagraf (tacrolimus prolonged release)
What this could lead to
If successful, this could help doctors give more precise doses of Advagraf to kidney transplant patients, potentially reducing side effects and improving outcomes.
What could go wrong
This is a small, completed pharmacokinetic study, not a large trial testing a new treatment. The findings may not change standard practice or apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Tours Hôpital Bretonneau
Tours, France
-
CHU de Nice
Nice, 06200, France
-
CHU de Rangueil
Toulouse, France
-
Hôpital Bicêtre
Le Kremlin-Bicêtre, France